Representative investor clients include:

• Deerfield Management
• Blackstone Life Sciences
• Digitalis Ventures
• Smash Capital
• Infinity Ventures
• Advance Publications

Representative private company transactions include:

• Apertura Gene Therapy, in its $67 million Series A financing and its foundational in-licenses from The Broad Institute of MIT and Harvard and Harvard Medical School.
• Loadsmart, a leading freight technology company, in its $200 million Series D financing.
• Galway Sustainable Credit, in its $250 million investment by funds managed by Macquarie Asset Management.
• Neomorph, in its $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs.
• Jaguar Gene Therapy in connection with its $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.
• Clearview AI, a leading facial recognition company, in connection with its $30 million Series B financing.

Representative life sciences collaboration transactions include:

• Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.
• Merck & Co. in connection with various strategic alliance transactions.
• Orchestra BioMed, in connection with its strategic collaborations with Medtronic and Terumo.

Cannabis Industry

• Canopy Growth Corporation, in connection with various M&A transactions.
• Cresco Labs, in connection with various M&A transactions.
• The Scotts Miracle-Gro Company, in connection with various M&A transactions.
• RIV Capital, in connection with various investment transactions.
• Turning Point Brands, in connection with various debt and minority equity investments.

• New NVCA Model Legal Documents – Now with Recent Market Data, Lexology, September 2022
• 2021: Venture Capital Year in Review, Lexology, March 2022
• Moderator, “Early-Stage Company Pitfalls and Risk Considerations,” the Cure Symposia by Deerfield, November 2021
• Moderator, “Beyond the Science: What Principal Investigators (PIs) Need to Consider When Negotiating,” the Cure Symposia by Deerfield, October 2021
• Moderator, “The Future of Venture Capital,” New York Venture Summit, July 2018
• Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018
• NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, November 2017
• Plenary Session Moderator, “In Pursuit of Growth, Savings, and Return on Investment: Pharma’s Quest for Innovation Partnerships,” Life Sciences Summit, November 2017
• Guest Lecturer, “Life Sciences Patent Law,” NYU School of Law, April 2017
• Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
• Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
• Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017
• Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal,January 2017, Vol. 37 Issue 1
• Panelist, “Dealmaking 2017: Exploring Academic-Industry Partnerships,” New York Pharma Forum, January 2017
• Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
• When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Shareholders, Law360, July 2016
• Legal Health Isn’t Easy for Digital Health Companies, TechCrunch, April 2016
• Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
• Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR, The M&A Lawyer, January 2016
• Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April 2015
• The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014